Skip to content

A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of ASP2905 in healthy young males, including an open-label two-period randomized crossover study to compare the pharmacokinetics under fasted and fed conditions

A double-blind, randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending oral doses of ASP2905 in healthy young males, including an open-label two-period randomized crossover study to compare the pharmacokinetics under fasted and fed conditions - ASP2905 SAD/food effect study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON32022
Enrollment
68
Registered
2008-04-01
Start date
2008-05-04
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ziekte van Alzheimer, schizofrenie Alzheimer's Disease and schizophreny

Interventions

nvt

Sponsors

Astellas Pharma
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Healthy young male subject, aged 18-50 years inclusive.

Exclusion criteria

Exclusion criteria: current clinically significant diseases or conditions or any clinical significant diseases or conditions in medical history.

Design outcomes

Primary

MeasureTime frame
nvt

Secondary

MeasureTime frame
nvt

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)